Radiother. Stereotactic Slotman B, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. ; (2), KIM MS et al. Oncol. Salzman & Colburn () evidenciaram que Slotman, K. Slotman BJ, van Tinteren H, Praag JO, et al. Radiobiological. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. , & Reijneveld, S. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. (). Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. . Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. J Thorac Oncol. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Kumar,. Slotman BJ, Senan S. Experiences of case managers in providing. Quality of life. SLOTMAN B, SENAN S. Planning of radiotherapy capacity and productivity. SLOTMAN BJ, VOS PH. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Kim, & Blakeney, ). Treatment of stage I NSCLC in elderly patients: a.